The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor

被引:321
作者
Basu, S
Nagy, JA
Pal, S
Vasile, E
Eckelhoefer, IA
Bliss, VS
Manseau, EJ
Dasgupta, PS
Dvorak, HF
Mukhopadhyay, D
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/87895
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Angiogenesis has an essential role in many important pathological and physiological settings. It has been shown that vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a potent cytokine expressed by most malignant tumors, has critical roles in vasculogenesis and both physiological and pathological angiogenesis. We report here that at non-toxic levels, the neurotransmitter dopamine strongly and selectively inhibited the vascular permeabilizing and angiogenic activities of VPF/VEGF. Dopamine acted through D2 dopamine receptors to induce endocytosis of VEGF receptor 2, which is critical for promoting angiogenesis, thereby preventing VPF/VEGF binding, receptor phosphorylation and subsequent signaling steps. The action of dopamine was specific for VPF/VEGF and did not affect other mediators of microvascular permeability or endothelial-cell proliferation or migration. These results reveal a new link between the nervous system and angiogenesis and indicate that dopamine and other D2 receptors, already in clinical use for other purposes, might have value in anti-angiogenesis therapy.
引用
收藏
页码:569 / 574
页数:6
相关论文
共 41 条
[31]   PHARMACOLOGICAL CHARACTERIZATION AND AUTORADIOGRAPHIC LOCALIZATION OF DOPAMINE-RECEPTORS IN THE PORTAL-VEIN [J].
RICCI, A ;
COLLIER, WL ;
AMENTA, F .
JOURNAL OF AUTONOMIC PHARMACOLOGY, 1994, 14 (01) :61-68
[32]   TUMOR-CELLS SECRETE A VASCULAR-PERMEABILITY FACTOR THAT PROMOTES ACCUMULATION OF ASCITES-FLUID [J].
SENGER, DR ;
GALLI, SJ ;
DVORAK, AM ;
PERRUZZI, CA ;
HARVEY, VS ;
DVORAK, HF .
SCIENCE, 1983, 219 (4587) :983-985
[33]  
Takechi Akihiko, 1994, Neurologia Medico-Chirurgica, V34, P729, DOI 10.2176/nmc.34.729
[34]   Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome [J].
Turner, HE ;
Nagy, Z ;
Gatter, KC ;
Esiri, MM ;
Harris, AL ;
Wass, JAH .
JOURNAL OF ENDOCRINOLOGY, 2000, 165 (02) :475-481
[35]   DOPAMINE - NOVEL ANTI-TUMOR AGENT ACTIVE AGAINST B-16 MELANOMA INVIVO [J].
WICK, MM .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1978, 71 (02) :163-164
[36]  
WICK MM, 1979, J NATL CANCER I, V63, P1465
[37]  
WICK MM, 1979, CANCER TREAT REP, V63, P991
[38]  
WICK MM, 1981, CANCER TREAT REP, V65, P861
[39]  
WICK MM, 1981, J NATL CANCER I, V66, P351
[40]  
WICK MM, 1980, CANCER RES, V40, P1414